These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9123539)

  • 1. Treatment of hepatitis B virus replication by ganciclovir in kidney transplant patients.
    Garnier JL; Chossegros P; Daoud S; Chevallier P; Dubernard JM; Trepo C; Touraine JL
    Transplant Proc; 1997; 29(1-2):817. PubMed ID: 9123539
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term ganciclovir therapy for hepatitis B virus infection after liver transplantation.
    Roche B; Samuel D; Gigou M; Feray C; Virot V; Majno P; Serraf L; David MF; Dusseaix E; Reynes M; Bismuth H
    J Hepatol; 1999 Oct; 31(4):584-92. PubMed ID: 10551379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged survival in fibrosing cholestatic hepatitis with long-term ganciclovir therapy.
    Jamal H; Regenstein F; Farr G; Perrillo RP
    Am J Gastroenterol; 1996 May; 91(5):1027-30. PubMed ID: 8633545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactivated fulminant hepatitis B virus replication after bone marrow transplantation: clinical course and possible treatment with ganciclovir.
    Mertens T; Köck J; Hampl W; Schlicht HJ; Tillmann HL; Oldhafer KJ; Manns MP; Arnold R
    J Hepatol; 1996 Dec; 25(6):968-71. PubMed ID: 9007727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lamivudine inhibits hepatitis B virus replication in kidney graft recipients.
    Goffin E; Horsmans Y; Cornu C; Squifflet JP; Pirson Y
    Transplantation; 1998 Aug; 66(3):407-9. PubMed ID: 9721816
    [No Abstract]   [Full Text] [Related]  

  • 6. Antiviral agents for hepatitis B.
    Gerin JL
    Hepatology; 1991 Jul; 14(1):198-9. PubMed ID: 2066069
    [No Abstract]   [Full Text] [Related]  

  • 7. Alteration of the dismal natural history of fibrosing cholestatic hepatitis secondary to hepatitis B virus with the use of lamivudine.
    Al Faraidy K; Yoshida EM; Davis JE; Vartanian RK; Anderson FH; Steinbrecher UP
    Transplantation; 1997 Sep; 64(6):926-8. PubMed ID: 9326423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients.
    Gish RG; Lau JY; Brooks L; Fang JW; Steady SL; Imperial JC; Garcia-Kennedy R; Esquivel CO; Keeffe EB
    Hepatology; 1996 Jan; 23(1):1-7. PubMed ID: 8550028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surrogate end-points for treatment trials of hepatitis B virus.
    Griffiths PD
    Rev Med Virol; 2010 Jul; 20(4):199-201. PubMed ID: 20586100
    [No Abstract]   [Full Text] [Related]  

  • 10. Ganciclovir treatment of active hepatitis B virus infection in a heart transplant patient.
    Anand BS; Yoffe B; Young JB
    J Clin Gastroenterol; 1996 Mar; 22(2):144-6. PubMed ID: 8742657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lamivudine therapy in renal allograft recipients with hepatitis B virus infection.
    Tsang WK; Tong KL; Chan HW
    Transplant Proc; 2003 Feb; 35(1):278-9. PubMed ID: 12591398
    [No Abstract]   [Full Text] [Related]  

  • 12. Navigating the maze of hepatitis B treatments.
    Lok AS
    Gastroenterology; 2007 Apr; 132(4):1586-94. PubMed ID: 17408643
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful control of subfulminant hepatitis related to lamivudine-resistant hepatitis B virus in an HIV-infected patient.
    Thabut D; Thibault V; Benhamou Y; Bernard B; Aubron-Olivier C; Poynard T; Di Martino V
    AIDS; 2001 Dec; 15(18):2463-4. PubMed ID: 11774835
    [No Abstract]   [Full Text] [Related]  

  • 14. In vitro models for studying hepatitis B virus drug resistance.
    Zoulim F
    Semin Liver Dis; 2006 May; 26(2):171-80. PubMed ID: 16673295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrence of hepatitis B in liver transplants treated with antiviral therapy.
    Marzano A; Debernardi-Venon W; Smedile A; Brunetto MR; Torrani Cerenzia MR; Actis GC; Zamboni F; Ghisetti V; Piantino P; David E; Salizzoni M; Rizzetto M
    Ital J Gastroenterol Hepatol; 1998 Feb; 30(1):77-81. PubMed ID: 9615271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lamivudine: a new strategy to suppress HBV replication in the pretransplant setting.
    Macedo G; Maia JC; Gomes A; Beleza M; Teixeira A; Ribeiro A
    Transplant Proc; 2000 Dec; 32(8):2642. PubMed ID: 11134737
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients.
    Benhamou Y; Dohin E; Lunel-Fabiani F; Poynard T; Huraux JM; Katlama C; Opolon P; Gentilini M
    Lancet; 1995 Feb; 345(8946):396-7. PubMed ID: 7845151
    [No Abstract]   [Full Text] [Related]  

  • 18. Management of special patient groups with hepatitis B virus infection: The EASL 2017 Clinical Practice Guidelines.
    Idilman R
    Turk J Gastroenterol; 2017 Nov; 28(6):518-521. PubMed ID: 29082891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral ganciclovir for treatment of lamivudine-resistant hepatitis B virus infection: a pilot study.
    Bozkaya H; Yurdaydin C; Bozdayi AM; Erkan O; Karayalcin S; Uzunalimoglu O
    Clin Infect Dis; 2002 Oct; 35(8):960-5. PubMed ID: 12355383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B virus (HBV) DNA assays (methods and practical use) and viral kinetics.
    Pawlotsky JM
    J Hepatol; 2003; 39 Suppl 1():S31-5. PubMed ID: 14708675
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.